Compare Starbucks Corp (SBUX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Twist Bioscience Corp — how do they compare? Starbucks Corp trades at $104.35 (market cap $119.45B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Starbucks Corp is far larger — about 21.9× Twist Bioscience Corp's market cap, and Starbucks Corp pays a 2.37% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SBUX | TWST | |
|---|---|---|
Market Cap | $119.45B | $5.45B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.37 | $102.88 |
52-Week Low | $78.46 | $24.16 |
Enterprise Value | $142.14B | $5.37B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $104.45, down 0.99% today, near its 52-week high with a bullish technical trend. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $37.18B in 2025, though net income fell to $1.86B, reflecting margin pressures. Analysts maintain a buy consensus with a $108.86 target, citing turnaround progress and cost-saving initiatives, including AI-driven software reductions.
SBUX's outlook is cautiously optimistic, supported by traffic growth and raised 2026 guidance, but profitability remains a concern with a high P/E of 80.01. Key risks include intense competition from Luckin Coffee and macroeconomic sensitivity. Institutional sentiment is positive, with 47% buy ratings, though investors should monitor execution on margin recovery and cost efficiency targets.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
